title: An indirect effect of an antibody on complement deposition and lysis of differently sensitized surrounding cells.
abstract: Lysis of papain-treated group A and B erythrocytes by human complement was studied by an anti-A (BRIC. 131) and an anti-B (BRIC. 30) IgM monoclonal antibody in 51Cr release assays. The indirect effect of membrane-bound antibody, i.e. its influence on complement binding to sensitized surrounding cells, was examined in a cold target competition test in which sensitized, non-labelled cells are present along with sensitized labelled cells and complement. The mode by which anti-A antibodies indirectly suppressed lysis of sensitized B cells up to 20-fold was studied by following C1q and C3b binding. C1q binding to both types of erythrocytes was not altered in mixed populations of erythrocytes in the presence of both antibodies. Binding of C3b to a mixture of both cell types was, however, suppressed, when both antibodies were present. C3b deposition in mixed cell populations did not reach a significantly higher extent than deposited to one type of erythrocyte alone. This was consistent with the results from competitive lysis and suggests that the anti-A captured most C3b at high anti-A concentrations and deprived the similarly sensitized B erythrocytes of complement. We think that this phenomenon is not due to an uneven removal of complement regulatory proteins from A and B erythrocytes by papain. Instead, the phenomenon might be due to an inherent property of anti-A mAb to better produce nucleation sites for C3 convertases which, upon binding factor B, better compete for the limiting factor D. A mathematical analysis of cold target competition experiment (containing 2430 individual measurements) also shows that the distribution of complement between the competing A and B erythrocyte population is uneven, since it predicts that in any given antibody combination the majority of complement is bound to A erythrocytes. This is consistent with the measured average percentage of lysis.
authors.affiliation: Department of Immunology, National Institute of Oncology, Budapest, Hungary.
authors.forename: T
authors.initials: T
authors.lastname: Bakács
authors.forename: H U
authors.initials: HU
authors.lastname: Lutz
authors.forename: G
authors.initials: G
authors.lastname: Tusnády
authors.forename: L
authors.initials: L
authors.lastname: Varga
authors.forename: A H
authors.initials: AH
authors.lastname: Merry
authors.forename: R R
authors.initials: RR
authors.lastname: Sim
mesh_terms: D000017:ABO Blood-Group System; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D015922:Complement C1q / Q000276:immunology; D003176:Complement C3 / Q000276:immunology; D003179:Complement C3b / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology*; D004912:Erythrocytes / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D066298:In Vitro Techniques; D051379:Mice; D010206:Papain / Q000494:pharmacology; D011485:Protein Binding
chemical_list: D000017:ABO Blood-Group System; D000911:Antibodies, Monoclonal; D003176:Complement C3; D007075:Immunoglobulin M; D015922:Complement C1q; D003179:Complement C3b; D003165:Complement System Proteins; D010206:Papain